1. Market Research
  2. > Wrinkles – Pipeline Review, H1 2013

Wrinkles – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 49 pages

Wrinkles – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Wrinkles - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Wrinkles, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Wrinkles. Wrinkles - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Wrinkles.
- A review of the Wrinkles products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Wrinkles pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Wrinkles.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Wrinkles pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Wrinkles - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Wrinkles Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Wrinkles 7
Wrinkles Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Wrinkles Therapeutics - Products under Development by Companies 14
Companies Involved in Wrinkles Therapeutics Development 15
Allergan, Inc. 15
Merz GmbH and Co. KGaA 16
Revance Therapeutics, Inc. 17
NovaLead Pharma Pvt. Ltd. 18
Novocell, Inc. 19
Wrinkles - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
onabotulinumtoxinA - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
onabotulinumtoxinA - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
NLP-02 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
onabotulinumtoxinA - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
FibroStem - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Autologous Human Platelet Lysate - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
RT-002 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Laminin Peptide YIGSR - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Wrinkles Therapeutics - Drug Profile Updates 35
Wrinkles Therapeutics - Discontinued Products 39
Wrinkles - Product Development Milestones 40
Featured News and Press Releases 40
Apr 17, 2012: Fibrocell Science Announces Publication Of LAVIV Pivotal Trial Data In Dermatologic Surgery 40
Apr 17, 2012: Merz Pharma Canada Announces Health Canada Approval Of XEOMIN COSMETIC 41
Mar 14, 2012: Merz Aesthetics And Merz Pharma Commit To Full Remediation Compliance In Allergan Lawsuit 41
Nov 07, 2011: Studies Show LAVIV Effectively Improves Appearance Of Smile Line Wrinkles 42
Oct 11, 2011: Medicis Receives FDA Approval For Lip Indication For Restylane 43
Oct 03, 2011: Fibrocell Science Announces Launch Of LAVIV 44
Jun 22, 2011: Fibrocell Receives FDA Approval For Azficel-T 45
Apr 27, 2011: FDA Panel Recommends Lip Indication for Medicis's RESTYLANE 45
Mar 10, 2011: Fibrocell Science Submits Final Data From Histology Study Of Azficel-T To FDA 46
Jan 12, 2011: Fibrocell Science Receives FDA Acceptance For Review Of Azficel-T Complete Response Submission 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49



List of Tables

Number of Products Under Development for Wrinkles, H1 2013 7
Products under Development for Wrinkles - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Allergan, Inc., H1 2013 15
Merz GmbH and Co. KGaA, H1 2013 16
Revance Therapeutics, Inc., H1 2013 17
NovaLead Pharma Pvt. Ltd., H1 2013 18
Novocell, Inc., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
Wrinkles Therapeutics - Drug Profile Updates 35
Wrinkles Therapeutics - Discontinued Products 39



List of Figures

Number of Products under Development for Wrinkles, H1 2013 7
Products under Development for Wrinkles - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Discovery and Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.